Trial Profile

A first human clinical trial assessing the safety, tolerance, pharmacodynamic characteristics and food effects of oral MRX-5 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRX 5 (Primary)
Indications Gram-negative infections; Nontuberculous mycobacterium infections
Focus Adverse reactions; First in man; Pharmacodynamics

08 Apr 2025 According to a MicuRx Pharmaceuticals media release, data from this trial will be presented at the 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025.
25 Oct 2024 According to a MicuRx Pharmaceuticals media release, company announced successful completion of Phase I clinical trial of MRX-5 in Australia, for treatment of nontuberculous mycobacterial (NTM) infections.
25 Oct 2024 Status changed to completed , according to MicuRx Pharmaceuticals media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com